What changed: Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma
Every dated change on the records linked to Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Guideline3Milestone7This record1
September 2026 · 1
2023 · 1
2022 · 1
2018 · 2
- 2018GuidelinePituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinomaGuideline European Society of Endocrinology guideline 2018: Aggressive PitNET or pituitary carcinoma
Temozolomide (standard schedule, at least 3 cycles before assessing response), with radiotherapy where not previously given; PRRT for SSTR-positive tumours, bevacizumab or checkpoint inhibitors in trials or case series after temozolomide failure.
- 2018MilestoneTemozolomideESE guideline for aggressive pituitary tumours and carcinomas
Temozolomide as first-line chemotherapy.